The choice of cut‐off is between the lower threshold that has demonstrated benefit from anti‐IL5 biologics in asthma, that is 150 cells/μL21 and current guidelines for directing the use of ICS in COPD 300 cells/μL.2 However, the cut‐off we chose is somewhat arbitrary and other cut‐offs could have been selected. Here, IL5 is linked to chronic obstructive pulmonary disease.